CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS
BEEN REQUESTED IS OMITTED AND IS NOTED AS FOLLOWS **REDACTED**. AN
UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
Amendment No 3
LICENSE AND COLLABORATION AGREEMENT
THIS AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (this “ Amendment ”), is entered into this 21
day of December 2007 (the “ Effective Date ”) by and between Santaris Pharma A/S , a Danish corporation having its principal
place of business at Hørsholm, Denmark (“ Santaris ”), and Enzon Pharmaceuticals, Inc. , a Delaware corporation having its
principal place of business at Bridgewater, New Jersey 08807 (“ Enzon ”). Santaris and Enzon may be referred to herein
individually as a “ Party ” or collectively, as the “ Parties ”.
WHEREAS, Enzon and Santaris entered into the License and Collaboration Agreement dated July 26, 2006 (the “
Agreement ”); and
WHEREAS, the Agreement was amended by Amendment No 1 dated 13
of June and Amendment No 2 dated 25
WHEREAS, Enzon and Santaris desire to amend and restate certain provisions of the Agreement.
WHEREAS, Enzon and Santaris changed the discovery process activities to allow Enzon to make certain mini-tox studies.
NOW, THEREFORE, in consideration of the covenants and obligations expressed herein and intending to be legally bound,
and otherwise bound by proper and reasonable conduct, the Parties agree as follows:
1. Capitalized terms used herein and not otherwise defined shall have the meanings given to them in the Agreement.
2. Section 5.4 of the Agreement is hereby amended and restated in its entirety as follows:
Compound Selection . Each LNA Compound delivered by Santaris to Enzon will be identified by
Santaris pursuant to the selection process set forth in Schedule 5.4A (the “ C